Abstract
We describe our experience, gained over the past 3 years, in the treatment of gastroesophageal junction adenocarcinoma, whose incidence has been increasing in recent years. In our series, we present the results to a follow-up of about 2 years for a total of 18 patients, treated with a particularly intensive combination treatment. It consists of neoadjuvant induction chemotherapy with the protocol docetaxel-cisplatin-5-fluorouracil for four cycles, before a concomitant chemoradiotherapy treatment. During combined phase, patients received an intensity-modulated radiotherapy and a weekly cisplatin. We will present the data to a long follow-up time and we will discuss the literature, the integration with thoracoabdominal surgery and other specific issues of this pathology.
Keywords:
gastroesophageal junction adenocarcinoma; intensity-modulated radiotherapy; simultaneous integrated boost.
MeSH terms
-
Adenocarcinoma / diagnostic imaging
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma / therapy*
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Chemoradiotherapy / methods
-
Disease-Free Survival
-
Esophageal Neoplasms / diagnostic imaging
-
Esophageal Neoplasms / mortality
-
Esophageal Neoplasms / pathology
-
Esophageal Neoplasms / therapy*
-
Esophagogastric Junction / diagnostic imaging
-
Esophagogastric Junction / pathology*
-
Female
-
Follow-Up Studies
-
Humans
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Neoadjuvant Therapy / adverse effects
-
Neoadjuvant Therapy / methods
-
Neoplasm Staging
-
Radiation Dosage
-
Radiotherapy, Intensity-Modulated / adverse effects
-
Radiotherapy, Intensity-Modulated / methods*
-
Stomach Neoplasms / diagnostic imaging
-
Stomach Neoplasms / mortality
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / therapy*
-
Taxoids / therapeutic use
-
Tomography, X-Ray Computed
Supplementary concepts
-
Adenocarcinoma Of Esophagus